Protect Pharmaceutical Corporation Logo

Protect Pharmaceutical Corporation

PRTT

(1.5)
Stock Price

0,60 USD

15.21% ROA

20.59% ROE

0.94x PER

Market Cap.

54.291.573,00 USD

1.3% DER

0% Yield

32.64% NPM

Protect Pharmaceutical Corporation Stock Analysis

Protect Pharmaceutical Corporation Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Protect Pharmaceutical Corporation Fundamental Stock Analysis
# Analysis Rating
1 ROE

ROE surpassing expectations (149.28%) highlights strong profitability and efficient use of shareholders' equity, making it an appealing investment prospect.

2 PBV

The stock's low PBV ratio (-5.42x) suggests it's undervalued, making it an attractive opportunity for investors.

3 DER

The stock has a low debt to equity ratio (-70%), which means it has a small amount of debt compared to the ownership it holds

4 ROA

The stock's ROA (0%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

5 Revenue Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

6 Net Profit Growth

The net profit of this company has shown no signs of growth over the last five years, suggesting limited profitability and making it a less attractive investment opportunity.

7 Assets Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

8 Graham Number

The company's Graham number suggests that its stock price is overestimated, implying that it may not be a promising investment opportunity.

9 Dividend Growth

Potential investors should be aware that the company's dividend growth has shown no upward trend in the past three years, indicating limited potential for increased returns.

10 Dividend

The company has not distributed any dividends in the past three years, which may raise concerns for investors looking for regular income from their investments.

11 Buffet Intrinsic Value

The company's stock appears overvalued (0) by Warren Buffett's formula, suggesting a less favorable investment opportunity as its market price exceeds its estimated intrinsic value.

Protect Pharmaceutical Corporation Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Protect Pharmaceutical Corporation Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Protect Pharmaceutical Corporation Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Protect Pharmaceutical Corporation Revenue
Year Revenue Growth
2009 0
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 5.940.843 100%
2021 78.794.000 92.46%
2022 81.799.000 3.67%
2023 136.158.000 39.92%
2024 181.796.000 25.1%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Protect Pharmaceutical Corporation Research and Development Expenses
Year Research and Development Expenses Growth
2009 0
2010 1.253.020 100%
2011 123.192 -917.13%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 1.909.000 100%
2022 1.746.000 -9.34%
2023 4.789.000 63.54%
2024 3.148.000 -52.13%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Protect Pharmaceutical Corporation General and Administrative Expenses
Year General and Administrative Expenses Growth
2009 2.150
2010 392.578 99.45%
2011 0 0%
2012 554.298 100%
2013 23.939 -2215.46%
2014 30.848 22.4%
2015 30.027 -2.73%
2016 41.707 28%
2017 115.400 63.86%
2018 2.828 -3980.62%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Protect Pharmaceutical Corporation EBITDA
Year EBITDA Growth
2009 -2.150
2010 -7.026.356 99.97%
2011 -1.550.109 -353.28%
2012 -554.298 -179.65%
2013 -23.939 -2215.46%
2014 -519.841 95.39%
2015 575.410 190.34%
2016 -41.707 1479.65%
2017 -115.400 63.86%
2018 -2.828 -3980.62%
2019 -1.870 -51.23%
2020 5.814.470 100.03%
2021 27.878.000 79.14%
2022 25.257.000 -10.38%
2023 47.540.000 46.87%
2024 53.904.000 11.81%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Protect Pharmaceutical Corporation Gross Profit
Year Gross Profit Growth
2009 0
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 5.862.586 100%
2021 44.365.000 86.79%
2022 41.576.000 -6.71%
2023 73.310.000 43.29%
2024 83.184.000 11.87%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Protect Pharmaceutical Corporation Net Profit
Year Net Profit Growth
2009 -2.150
2010 -7.026.356 99.97%
2011 -270.109 -2501.3%
2012 -554.298 51.27%
2013 -23.939 -2215.46%
2014 458.145 105.23%
2015 -635.464 172.1%
2016 -41.707 -1423.64%
2017 -122.611 65.98%
2018 -17.732 -591.47%
2019 -1.873 -846.72%
2020 5.813.100 100.03%
2021 20.208.000 71.23%
2022 22.442.000 9.95%
2023 45.912.000 51.12%
2024 53.904.000 14.83%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Protect Pharmaceutical Corporation Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2009 0
2010 -173 100%
2011 -6 -2766.67%
2012 -12 50%
2013 -1 0%
2014 8 100%
2015 -1 900%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 1 0%
2024 1 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Protect Pharmaceutical Corporation Free Cashflow
Year Free Cashflow Growth
2009 0
2010 0 0%
2011 22.171 100%
2012 -21.411 203.55%
2013 -179 -11861.45%
2014 -179 0%
2015 -17.805 98.99%
2016 -14.158 -25.76%
2017 0 0%
2018 -28 100%
2018 -36.086 99.92%
2019 11.975 401.34%
2020 -13.025.710 100.09%
2021 -64.898.000 79.93%
2022 -69.017.000 5.97%
2023 4.042.000 1807.5%
2024 2.583.000 -56.48%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Protect Pharmaceutical Corporation Operating Cashflow
Year Operating Cashflow Growth
2009 0
2010 0 0%
2011 22.171 100%
2012 -21.411 203.55%
2013 -179 -11861.45%
2014 -179 0%
2015 -17.805 98.99%
2016 -14.158 -25.76%
2017 0 0%
2018 -28 100%
2018 -36.086 99.92%
2019 11.975 401.34%
2020 6.774.290 99.82%
2021 10.505.000 35.51%
2022 -67.199.000 115.63%
2023 4.042.000 1762.52%
2024 2.583.000 -56.48%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Protect Pharmaceutical Corporation Capital Expenditure
Year Capital Expenditure Growth
2009 0
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2018 0 0%
2019 0 0%
2020 19.800.000 100%
2021 75.403.000 73.74%
2022 1.818.000 -4047.58%
2023 0 0%
2024 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Protect Pharmaceutical Corporation Equity
Year Equity Growth
2009 -5.231
2010 -459.203 98.86%
2011 -425.562 -7.91%
2012 -577.189 26.27%
2013 -595.128 3.01%
2014 -120.983 -391.91%
2015 -100.447 -20.44%
2016 -20.830 -382.22%
2017 -143.441 85.48%
2018 -151.600 5.38%
2018 -196.289 22.77%
2019 -54.267 -261.71%
2020 5.889.674 100.92%
2021 205.640.000 97.14%
2022 229.983.000 10.58%
2023 276.362.000 16.78%
2024 296.539.000 6.8%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Protect Pharmaceutical Corporation Assets
Year Assets Growth
2009 0
2010 0 0%
2011 22.171 100%
2012 860 -2478.02%
2013 681 -26.28%
2014 502 -35.66%
2015 7 -7071.43%
2016 0 0%
2017 0 0%
2018 20.072 100%
2018 91 -21957.14%
2019 140.753 99.94%
2020 20.014.992 99.3%
2021 366.253.000 94.54%
2022 344.455.000 -6.33%
2023 366.360.000 5.98%
2024 378.268.000 3.15%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Protect Pharmaceutical Corporation Liabilities
Year Liabilities Growth
2009 5.231
2010 459.203 98.86%
2011 447.733 -2.56%
2012 578.049 22.54%
2013 595.809 2.98%
2014 121.485 -390.44%
2015 100.454 -20.94%
2016 20.830 -382.26%
2017 143.441 85.48%
2018 171.672 16.44%
2018 50.280 -241.43%
2019 64.128 21.59%
2020 14.125.318 99.55%
2021 160.613.000 91.21%
2022 114.472.000 -40.31%
2023 89.998.000 -27.19%
2024 81.729.000 -10.12%

Protect Pharmaceutical Corporation Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
3.07
Net Income per Share
1
Price to Earning Ratio
0.94x
Price To Sales Ratio
0.31x
POCF Ratio
3.94
PFCF Ratio
4.75
Price to Book Ratio
0.18
EV to Sales
0.26
EV Over EBITDA
0.78
EV to Operating CashFlow
3.35
EV to FreeCashFlow
4.05
Earnings Yield
1.06
FreeCashFlow Yield
0.21
Market Cap
0,05 Bil.
Enterprise Value
0,05 Bil.
Graham Number
10.78
Graham NetNet
1.3

Income Statement Metrics

Net Income per Share
1
Income Quality
0.24
ROE
0.21
Return On Assets
0.15
Return On Capital Employed
0.2
Net Income per EBT
0.97
EBT Per Ebit
1
Ebit per Revenue
0.34
Effective Tax Rate
0.25

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0.03
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.52
Operating Profit Margin
0.34
Pretax Profit Margin
0.34
Net Profit Margin
0.33

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
0.24
Free CashFlow per Share
0.2
Capex to Operating CashFlow
0.17
Capex to Revenue
0.01
Capex to Depreciation
0
Return on Invested Capital
0.19
Return on Tangible Assets
0.15
Days Sales Outstanding
143.89
Days Payables Outstanding
21.4
Days of Inventory on Hand
356.44
Receivables Turnover
2.54
Payables Turnover
17.06
Inventory Turnover
1.02
Capex per Share
0.04

Balance Sheet

Cash per Share
1,10
Book Value per Share
5,16
Tangible Book Value per Share
5.16
Shareholders Equity per Share
5.16
Interest Debt per Share
0.07
Debt to Equity
0.01
Debt to Assets
0.01
Net Debt to EBITDA
-0.14
Current Ratio
2.64
Tangible Asset Value
0,30 Bil.
Net Current Asset Value
0,13 Bil.
Invested Capital
278002000
Working Capital
0,13 Bil.
Intangibles to Total Assets
0
Average Receivables
0,07 Bil.
Average Payables
0,01 Bil.
Average Inventory
82997000
Debt to Market Cap
0.07

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Protect Pharmaceutical Corporation Dividends
Year Dividends Growth

Protect Pharmaceutical Corporation Profile

About Protect Pharmaceutical Corporation

Protect Pharmaceutical Corporation primarily focuses on crop farming and agricultural businesses. It acquires the Can Noguera property located in Selva Girona region in Spain. Its property consists of 60 hectares of arable land, 390 hectares of forests, 6 mineral and freshwater wells, and 3000 square meters of built properties. The company was formerly known as Pro-Tect, Inc. and changed its name to Protect Pharmaceutical Corporation in March 2010. Protect Pharmaceutical Corporation was founded in 1987 and is based in Las Vegas, Nevada.

CEO
Mr. Alan Crooks
Employee
0
Address
4876 Cecile Avenue
Las Vegas, 89115

Protect Pharmaceutical Corporation Executives & BODs

Protect Pharmaceutical Corporation Executives & BODs
# Name Age
1 Mr. Ali Yildiz
President
70
2 Mr. Alan Crooks
Chief Executive Officer & Director
70

Protect Pharmaceutical Corporation Competitors